Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15444MR)

This product GTTS-WQ15444MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15444MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3725MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ11019MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ14225MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ1943MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ2867MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ553MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ3053MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ14060MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3918
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW